Stay alert, beware of scamsters - know more

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open40.41
High40.41
Low40.41
Prev. Close39.62
Avg. Traded Price40.41
Volume2,45,848

MARKET DEPTH

info2
Total bid4062548.00
Total ask0.00
OrdersQtyBid
1841849040.41
229202547240.4
18850018640.39
16150015640.38
13350012840.37
AskQtyOrders
000
000
000
000
000

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

41.213 days ago
41.213 days ago
arrow

LOWER/UPPER CIRCUITS

39.61
41.21
arrow
Take Solutions Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Net Profit,rose 131.32% in the last year to ₹37.47 Cr. Its sector's average net profit growth for the last fiscal year was 90.21%.
noteReturn on Equity(ROE),for the last financial year was 182.52%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.
noteDebt to Equity Ratio,is zero as the company is debt-free.
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : -32.62%
Net profit growth 5Y CAGR : %

About TAKE Solutions Limited

TAKE Solutions Limited is a publicly listed Indian company delivering domain-intensive services and solutions in Life Sciences, Software, and Information Technology. The company specializes in full-service Clinical, Regulatory, and Safety offerings spanning clinical trials, regulatory submissions, and post-marketing safety, backed by industry-specific technology and analytics. Its global clientele includes innovator biopharmaceutical and medical device companies, generics manufacturers, and U.S. federal agencies such as CDC and DoD. The company is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE), with its registered office in Chennai, Tamil Nadu.

 

TAKE Solutions operates within a single segment, “Life Sciences and Support Services,” reflecting a focused domain concentration. As of March 31, 2025, TAKE Solutions Pte Ltd, Singapore holds 52.90% equity share capital, controlling operational and financial policies. The Group serves clients worldwide, leveraging a team of life sciences experts, process excellence, and bespoke technology to deliver outcomes to pharmaceutical, biotech, and medical device companies.

 

The company had two subsidiaries as of March 31, 2025. A significant portfolio action was the disinvestment of its material subsidiary, Ecron Acunova Limited, approved in October 2024 and completed by November 2024, allowing strategic focus on core Life Sciences priorities.

TAKE Solutions Limited Business Segment and Geographic Presence  

The company reports a single operating segment: Life Sciences and Support Services, with global customers in pharmaceuticals, biotech, and medical devices. Geographic operations span across India and global markets, directly and via subsidiaries.

 

TAKE Solutions engages comprehensively in Life Sciences services, including clinical research, generics development, regulatory affairs, pharmacovigilance, and safety, supported by technology platforms and analytics. It offers full-cycle solutions from clinical trials to post-marketing surveillance, technology-enabled regulatory compliance, and data sciences tailored to client needs globally.

TAKE Solutions Limited Key Management

  • Vedamirtham Venkatesan – Executive Director & Chief Financial Officer
  • Srinivasan H. R. – Director (Non-Executive)
  • Cecily Dheepa – Director
  • Sonia Bhimrajka – Company Secretary

Latest Updates on TAKE Solutions Limited

  • Disinvestment of 100% stake in Ecron Acunova Limited finalized in Q3 FY 2025 per Board and shareholder approvals.
  • Board reconstitution with new appointments and resignations during the year, including Sonia Bhimrajka appointed as Company Secretary in May 2025.
  • Internal financial controls were reported inadequate by auditors; strengthening compliance, governance, and financial discipline is a priority.
  • No change in business nature or equity capital during FY 2024-25.
  • Investor relations maintained via the company website with compliance to regulatory disclosures and annual meeting schedules.
personal

Grow your wealth with more research recommendations

+91

Frequently Asked Questions

Provides domain-intensive Life Sciences services including clinical research, regulatory submissions, pharmacovigilance, supported by technology and analytics.

Based in Chennai, India, serving a global client base including U.S. federal agencies such as CDC and DoD.

The company had two subsidiaries as of March 31, 2025. TAKE Solutions Pte Ltd, Singapore, owns 52.90% equity and exercises control.